Interview with Robert Coffin, inventor of T-VEC: the first oncolytic immunotherapy approved for the treatment of cancer. 
Interviewed by Ellen Clarke, Commissioning Editor, Future Science Group.  Robert Coffin is co-founder and CEO of Replimune.  Previously he was Founder and CTO of BioVex Inc, a spin out from his research group at University College London in 1999.  He was the inventor of all BioVex products including OncoVEXGM-CSF (talimogene laherparepvec; T-VEC; Imlygic) and oversaw all research and clinical development including bringing T-VEC through to two pivotal Phase 3 studies in melanoma and head and neck cancer.  BioVex was acquired by Amgen in 2011 where he was VP Global Development until 2013.  T-VEC was approved by the FDA for use in advanced melanoma in October 2015, the first oncolytic therapy or gene therapy to be approved in USA.  He was awarded a PhD in virology from Imperial College London prior to his move to University College London in 1991.